Tocilizumab for critically ill patients with refractory anti-NMDAR encephalitis: a case report. (PubMed, Front Immunol) - Sep 17, 2026 - "Rituximab (RTX) was started 9 months after onset. Although causality cannot be established, TCZ may offer a rapid and time-limited immunomodulatory option for carefully selected ICU patients when conventional second-line therapies are unsuitable. Prospective controlled studies are required to determine its efficacy and optimal timing."
Journal • Acute Kidney Injury • CNS Disorders • Critical care • Epilepsy • Hematological Disorders • Hepatitis B • Infectious Disease • Inflammation • Movement Disorders • Nephrology • Psychiatry • Renal Disease • Septic Shock • Thrombocytopenia • IL6
|
|
Ana Luíza Vieira de Araújo; J H F Ferreira; Lívia Almeida Dutra; Marcos Vinicius Tadao Fujino; Mauricio Elias Nunes da Silva; Renato Pierre Lima
|